Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Nov
15
Today In Oncology
Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care
Are Young Patients With Cancer Discussing Fertility Preservation With Physicians?
Prostatectomy With or Without Postprostatectomy Radiotherapy and Long-Term HRQOL in Localized Prostate Cancer
In Case You Missed It: Roundup From ESMO Congress 2024
Exploring Issues in Oncofertility
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo